Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility.

about

Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications

P2860

Q26775925-1946B732-8C60-48BE-977F-CB2C5114B705 Q36460566-218AE44A-46AD-4D05-BB5F-6131C362D30D

P2860

Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility.

Item

http://www.wikidata.org/entity/Q38248275

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Avanafil for erectile dysfunct ...... macology and clinical utility.

@en

type

Item

label

Avanafil for erectile dysfunct ...... macology and clinical utility.

@en

prefLabel

Avanafil for erectile dysfunct ...... macology and clinical utility.

@en

P1476

Avanafil for erectile dysfunct ...... macology and clinical utility.

@en

P2093

Daniel Rittenberg

http://www.w3.org/2001/XMLSchema#string

Eric G Katz

http://www.w3.org/2001/XMLSchema#string

Ronny Bw Tan

http://www.w3.org/2001/XMLSchema#string

Wayne J Hellstrom

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation

Udenafil: efficacy and tolerability in the management of erectile dysfunction

Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events.

Clinical and psychosocial characteristics of men with erectile dysfunction: baseline data from ExCEED.

Physiology of penile erection and pathophysiology of erectile dysfunction

Chapter 1: The management of erectile dysfunction: an AUA update.

Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties.

Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.

Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.

Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.

P304

701-711

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/TCRM.S57610

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265558937

http://www.w3.org/2001/XMLSchema#string

P698

25210457

http://www.w3.org/2001/XMLSchema#string

P932

4155803

http://www.w3.org/2001/XMLSchema#string

Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility.

about

P2860

P2860

Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932